Company intelligence / Profile preview

Med ePad

Liverpool, Merseyside, United Kingdom

Ownership: Private
Development stage: Other

Overview

Early research showed significant cost reductions: patients with chronic obstructive pulmonary disease monitored remotely showed 50% reduction in hospital admissions and 55% reduction in home exacerbations; post-discharge diabetes patients showed 42% drop in overall cost per patient

Therapeutic areas: Women's HealthOtherEndocrinologyCardiovascularInfectious DiseasesPulmonologyOncology
Modalities: Device (software application platform for touchscreen tablets)
Industry: Digital Health Medical Devices

Partnerships

National Health Service (NHS) - applications developed in conjunction with NHS professionals

Beyond the preview

Go deeper on Med ePad.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Med ePad.

Explore the full profile